NCT00603460View on ClinicalTrials.gov

DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

March 31, 2013

Conditions
Ovarian CancerPrimary Peritoneal Cancer
Interventions
BIOLOGICAL

DCVax-L and T Cells

"Arm A~* Optional DCVax-L prior to chemotherapy~* Apheresis~* Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~* Infusion of activated T cells~* DCVax-L vaccine~* End of study visit~Arm B~* Optional DCVax-L prior to chemotherapy~* Apheresis~* Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~* Infusion of activated T cells~* DCVax-L vaccine~* Oral cyclophosphamide (one week on/one week off) for a total for a total of 6 weeks~* End of study visit"

Trial Locations (1)

19104

University of Pennsylania, Philadelphia

Sponsors

Collaborators (1)

Northwest Biotherapeutics
All Listed Sponsors
collaborator

Northwest Biotherapeutics

INDUSTRY

lead

University of Pennsylvania

OTHER

NCT00603460 - DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter